Critical Outcome Technologies Updates COTI-2 Study

Critical Outcome Technologies (TSXV:COT; OTCQB:COTQF) announced the completion of the dose escalation portion of their Phase 1 study of COTI-2 with women with advanced gynecologic cancers.
As quoted in the press release:

In addition, COTI announced that it has initiated an expansion arm of its Phase 1 study in patients with head and neck squamous cell carcinoma (HNSCC). The Dose Escalation Committee (DEC), comprised of clinical site investigators, an independent medical monitor and Company representatives, met on Friday, August 11, 2017. The initial clinical data were reviewed and the DEC unanimously voted to complete this phase of the trial and progress the study into the HNSCC indication at a starting dose of 1.0 mg/kg.

Click here to read the full press release.
 

Source: www.marketwired.com